Boehringer Ingelheim
This website is for UK Healthcare Professionals. If you are a patient or member of the public please visit our public website here
Find adverse event reporting information at the bottom of this page
Contact
Boehringer Ingelheim
Boeringer Ingelheim
Boehringer Ingelheim
Boeringer Ingelheim
Boehringer Ingelheim
Boeringer Ingelheim
  • Diseases

    Diseases

    • Diseases
    • Asthma
    • Chronic Heart Failure (CHF)
    • Chronic Kidney Disease (CKD)
    • COPD
    • Dermatology
    • Idiopathic Pulmonary Fibrosis (IPF)
    • Progressive Pulmonary Fibrosis (PPF)
    • Stroke
    • Type 2 Diabetes
  • Products

    Products

    • Products
    • JARDIANCE® (empagliflozin)
    • METALYSE 25 mg (tenecteplase)
    • OFEV® (nintedanib)
    • SPEVIGO (spesolimab)

    • SPIOLTO® Respimat® (tiotropium/olodaterol)
    • SPIRIVA® Respimat® (tiotropium)
    • TRAJENTA® (linagliptin)
  • Resources

    Resources

    • Resources
      • Healthcare Professional Resources
      • Cardio Renal Metabolism
      • Respiratory
  • Click here to join
    our mailing list to hear
    news & updates about our products
    Opens in new tab
  • Find adverse event reporting information at the bottom of this page
  • Contact
Boeringer Ingelheim

Prescribing Information


SPIRIVA (tiotropium) Respimat inhaler device with cap removed while releasing solution into the air plus logo and male patient

SPIRIVA® Respimat® (tiotropium) for severe asthma

SPIRIVA Respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
About severe asthma
Meet your patient
LAMA (tiotropium) in severe asthma
Why SPIRIVA Respimat?
Respiratory resources
SPIOLTO (tiotropium + olodaterol) Respimat inhaler device with cap removed while releasing solution into the air plus logo and female patient

SPIOLTO® Respimat® (tiotropium + olodaterol) for COPD

SPIOLTO Respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
Meet your patients
LAMA + LABA (tiotropium + olodaterol)
Switching from a LAMA
SMI or DPI?
Respiratory resources

COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic receptor antagonist; LABA, long-acting beta agonist; DPI, dry powder inhaler; SMI, soft mist inhaler.

PC-GB-109568 V1 January 2025

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

  1. Home
  2. Respiratory hub
Boehringer Ingelheim
BI LOGO
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Sitemap
  • Terms of Use
  • Accessibility Statement

This information is for UK Healthcare Professionals only. Products discussed herein may have different labelling in different countries. 
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Notice.

Copyright © 2021-2025 Boehringer Ingelheim, Inc. All rights reserved. PC-GB-110791 December 2024.